Several studies are showing that mTOR inhibitors, such as DL001 ( dactolisib) are up to 40 times more effective in inhibiting mTOR1 without inhibiting mTOR2 ( which leads to the undesired side effects of Rapamycin ( blood sugar effects , elevation of blood cholesterol and immune suppression)
These drugs would seem to allow for the higher dosing seemingly needed in humans to have a significant effect on heath span and lifespan( based on the recent results of a marmoset study, where very high does of Rapamycin yielded only a 15% increase in median lifespan.
4 Likes
Yes - the new compounds by Aeovian and Tornado Therapeutics are very promising. But they are in early stage clinical trials and even in the best of cases are unlikely to be available for another 7 to 10 years given the typical FDA approval process they have to go through. Also, they are likely to be very expensive, as new drugs typically are… Everolimus (a rapalog) recently came off patent, but was priced at $15,000/month until the end of patent life, so we’ll see what the new mTORC1 specific drugs are priced at…
2 Likes
KarlT
#3
Do you know what disease these drugs will treat to get FDA approval?
Aeovian: First Cohort of Participants Dosed in Phase 1 Clinical Trial with Lead Development Candidate AV078 Intended for the Treatment of Seizures Associated with Tuberous Sclerosis Complex (TSC)
Tornado Therapeutics: Viral Respiratory Tract Infections, Oncology
5 Likes
59vw
#5
It will be interesting to see how these perform in ITP and perhaps other (dog, marmoset) studies. I think it’s important to remember that mtorc1 inhibition “good”, mtorc2 inhibition “bad” is a theory that has virtually no proof behind it. It may be you need a little of both. Also, since mtor is present in both complexes I’d welcome an explanation for how you inhibit one without affecting the other.
1 Like
